```html

Quinacrine Rash – A Complete Guide

What is Quinacrine Rash?

Quinacrine rash is a cutaneous reaction that appears after exposure to quinacrine, a synthetic antimalarial and anti‑inflammatory drug also known as mepacrine. The rash typically presents as red, itchy, and sometimes painful patches or papules that may coalesce into larger plaques. While quinacrine is used less frequently today, it is still prescribed for certain parasitic infections (e.g., giardiasis), autoimmune disorders, and occasionally in dermatology for conditions such as lichen planus.

The reaction can vary from a mild, localized erythema to a widespread, severe eruption resembling Stevens‑Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN). Recognizing the pattern of a quinacrine rash is essential because the drug can also cause systemic side effects such as hepatotoxicity, hemolysis (especially in G6PD‑deficient patients), and neurotoxicity.

Common Causes

Quinacrine rash is a drug‑induced eruption, but similar‑looking rashes can be triggered by other conditions. Below are eight‑to‑ten common causes that either mimic or coexist with quinacrine‑related skin findings:

• Quinacrine (mepacrine) therapy: The primary cause; rash typically starts 5‑14 days after the first dose.
• Other antimalarials (chloroquine, hydroxychloroquine): Cross‑reactivity can produce a similar rash.
• Contact dermatitis: Irritants or allergens (nickel, fragrances) can cause a red, itchy rash that may be confused with a drug eruption.
• Photosensitivity reactions: Quinacrine is photosensitizing; sun exposure can exacerbate the rash.
• Viral exanthems (e.g., parvovirus B19, hepatitis B/C): Viral rashes often present with systemic symptoms.
• Autoimmune skin diseases (lupus erythematosus, dermatomyositis): These can present with photosensitive rashes that look similar.
• Stevens‑Johnson syndrome / Toxic epidermal necrolysis: Severe drug reactions that may start as a quinacrine rash and rapidly progress.
• Atopic dermatitis flare: Chronic itchy rash that can be worsened by drug exposure.
• Scabies infestation: Intense itching with burrow‑like lesions, sometimes misinterpreted as drug rash.
• Folliculitis or bacterial skin infection: Red papules/pustules that may appear after drug-induced skin breakdown.

Associated Symptoms

Quinacrine rash rarely occurs in isolation. Look for accompanying signs that can help differentiate it from other dermatologic problems:

• Pruritus (itching): Often the most bothersome symptom; scratching can lead to secondary infection.
• Burning or stinging sensation: Typical of photosensitive drug eruptions.
• Fever or chills: May indicate a systemic drug reaction.
• Joint pain or arthralgia: Seen when quinacrine is used for rheumatologic conditions.
• Oral mucosal lesions: Painful ulcers or erythema, a clue for SJS/TEN.
• Swelling of the face, lips, or tongue (angioedema): Suggests a more severe hypersensitivity.
• Dark urine or jaundice: Possible hepatic involvement from quinacrine toxicity.
• Fatigue, headache, or dizziness: Systemic side effects of quinacrine.

When to See a Doctor

Because quinacrine can trigger life‑threatening reactions, prompt medical evaluation is crucial when any of the following occur:

• Rash spreads to more than 30% of body surface area.
• Blistering, detachment of skin, or target‑shaped lesions appear.
• Persistent fever >38°C (100.4°F) lasting more than 24 hours.
• Severe itching that interferes with sleep or daily activities.
• Swelling of the eyes, lips, tongue, or throat.
• Signs of infection (increased pain, pus, red streaks, fever).
• Any new symptoms of liver dysfunction (yellow skin or eyes, dark urine).
• History of G6PD deficiency—any rash warrants immediate review.

Diagnosis

Diagnosing a quinacrine rash combines a careful history, physical examination, and selective testing.

1. Detailed medication review

The physician will ask about the dose, duration, and timing of quinacrine therapy, as well as any other drugs, supplements, or over‑the‑counter products.

2. Physical examination

Key elements include:

• Distribution pattern (often trunk and upper limbs, sparing the face unless photosensitized).
• Lesion morphology (macules, papules, plaques, vesicles, or bullae).
• Presence of mucosal involvement.
• Signs of secondary infection.

3. Laboratory tests (as indicated)

• Complete blood count (CBC): Detects eosinophilia or anemia.
• Liver function tests (AST, ALT, bilirubin): Rule out hepatic toxicity.
• Renal panel: Baseline before stopping quinacrine.
• G6PD activity assay: Important if the patient is from a high‑risk population.
• Patch testing: Rarely performed; helps confirm drug hypersensitivity in specialized centers.

4. Skin biopsy (when uncertain)

A 4‑mm punch biopsy can differentiate a drug eruption from autoimmune or infectious dermatoses. Histology typically shows vacuolar interface dermatitis, eosinophilic infiltrate, and occasional necrotic keratinocytes.

5. Phototesting (if photosensitivity is suspected)

Exposing a small skin area to controlled UV light helps confirm a photosensitive component.

Treatment Options

Management focuses on stopping the offending agent, relieving symptoms, and preventing complications.

1. Discontinue quinacrine

Immediate cessation is the first and most important step. In most cases, the rash improves within 3‑5 days after stopping the drug.

2. Symptomatic relief

• Topical corticosteroids: Low‑ to mid‑potency steroids (e.g., hydrocortisone 1% or triamcinolone 0.1%) applied twice daily can reduce inflammation.
• Oral antihistamines: Non‑sedating options such as cetirizine 10 mg daily help control itch.
• Cool compresses or oatmeal baths: Provide soothing relief for widespread erythema.
• Moisturizers: Fragrance‑free emollients restore barrier function.

3. Systemic therapy (for moderate‑severe or extensive reactions)

• Oral corticosteroids: Prednisone 0.5‑1 mg/kg/day for 5‑7 days, then taper, may be prescribed if there is extensive skin involvement or systemic symptoms.
• Immunomodulators: In refractory cases, agents like cyclosporine or mycophenolate have been used, but only under specialist supervision.

4. Treatment of complications

• Secondary bacterial infection: Oral antibiotics (e.g., cephalexin 500 mg q6h) based on culture results.
• Fluid and electrolyte management: Required for extensive skin loss resembling TEN.
• Photoprotection: Broad‑spectrum sunscreen (SPF 30+) and protective clothing to prevent further photosensitive worsening.

5. Follow‑up care

Patients should be re‑evaluated within 1‑2 weeks to ensure resolution and to discuss alternative therapies for the underlying condition that required quinacrine.

Prevention Tips

While the need for quinacrine is decreasing, the following strategies can reduce the risk of rash when the drug is necessary:

• Confirm indication: Use quinacrine only when first‑line agents are unsuitable.
• Screen for G6PD deficiency: Perform a test before starting therapy, especially in individuals of African, Mediterranean, or Asian descent.
• Start with a low dose: Titrating up allows early detection of hypersensitivity.
• Avoid sun exposure: Wear sunscreen, hats, and protective clothing for at least 2 weeks after initiating treatment.
• Monitor closely: Keep a daily diary of skin changes, fever, or new symptoms during the first month of therapy.
• Educate caregivers: Children and elderly patients may not report itching promptly; a caregiver should inspect the skin regularly.
• Use alternative drugs when possible: Hydroxychloroquine or mefloquine may have a lower rash risk for certain infections.
• Report any rash immediately: Early discontinuation often prevents progression to severe reactions.

Emergency Warning Signs

---

**References**

• Mayo Clinic. “Drug Rash.” https://www.mayoclinic.org/drug-rash. Accessed June 2026.
• Cleveland Clinic. “Quinacrine (Mepacrine) – Uses, Side Effects, and Interactions.” https://my.clevelandclinic.org/health/drugs/14755-quinacrine.
• National Institutes of Health. “G6PD Deficiency.” NIH Genetic and Rare Diseases Information Center. https://rarediseases.info.nih.gov/diseases/6422/g6pd-deficiency.
• World Health Organization. “Guidelines for the Treatment of Malaria.” WHO, 2023.
• American Academy of Dermatology. “Drug Eruptions.” https://www.aad.org/public/diseases/a-z/drug-eruptions.
• Centers for Disease Control and Prevention. “Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.” CDC, 2022. https://www.cdc.gov/cpse/stevens-johnson-syndrome.html.

```